Characterization of a receptor for macrophage inflammatory protein 1 alpha and related proteins on human and murine cells

Autor: Gerard Graham, Zhou L, Ja, Weatherbee, Ml, Tsang, Napolitano M, Wj, Leonard, Ib, Pragnell

Publikováno v: Europe PubMed Central

Macrophage inflammatory protein 1 alpha (MIP-1 alpha) is a potent stem cell inhibitor and a member of a large and expanding family of related cytokines. In an effort to understand the molecular basis of the activities of MIP-1 alpha, we have sought t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::e01b51edd31b17170a4a1213200ce07b
http://europepmc.org/abstract/med/8385474

Publisher Correction: Role of thymic stromal lymphopoietin in allergy and beyond.

Autor: Ebina-Shibuya R; Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan., Leonard WJ; Laboratory of Molecular Immunology, Immunology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA. leonardw@nhlbi.nih.gov.

Publikováno v: Nature reviews. Immunology [Nat Rev Immunol] 2024 Nov; Vol. 24 (11), pp. 846.

Engineered cytokine/antibody fusion proteins improve IL-2 delivery to pro-inflammatory cells and promote antitumor activity.

Autor: Leonard EK; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Tomala J; Institute of Biotechnology of the Academy of Sciences of the Czech Republic, Vestec, Czech Republic.; Department of Chemical & Biomolecular Engineering and., Gould JR; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Leff MI; Department of Biology, Johns Hopkins University, Baltimore, Maryland, USA., Lin JX; Laboratory of Molecular Immunology, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA., Li P; Laboratory of Molecular Immunology, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA., Porter MJ; Department of Chemistry, Johns Hopkins University, Baltimore, Maryland, USA., Johansen ER; Department of Chemistry, Johns Hopkins University, Baltimore, Maryland, USA., Thompson L; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Cao SD; Department of Chemical & Biomolecular Engineering and., Hou S; Department of Plastic & Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Henclova T; Institute of Biotechnology of the Academy of Sciences of the Czech Republic, Vestec, Czech Republic., Huliciak M; Institute of Biotechnology of the Academy of Sciences of the Czech Republic, Vestec, Czech Republic.; Department of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, USA., Sargunas PR; Department of Chemical & Biomolecular Engineering and., Fabilane CS; Program in Molecular Biophysics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Vaněk O; Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic., Kovar M; Laboratory of Tumor Immunology, Institute of Microbiology of the Academy of Sciences of the Czech Republic, Prague, Czech Republic., Schneider B; Institute of Biotechnology of the Academy of Sciences of the Czech Republic, Vestec, Czech Republic., Raimondi G; Vascularized Composite Allotransplantation Laboratory, Department of Plastic and Reconstructive Surgery., Leonard WJ; Laboratory of Molecular Immunology, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA., Spangler JB; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Chemical & Biomolecular Engineering and.; Translational Tissue Engineering Center.; Department of Oncology.; Bloomberg-Kimmel Institute for Cancer Immunotherapy.; Sidney Kimmel Comprehensive Cancer Center; and.; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Publikováno v: JCI insight [JCI Insight] 2024 Sep 24; Vol. 9 (18). Date of Electronic Publication: 2024 Sep 24.

LIM-domain-only 4 (LMO4) enhances CD8 ⁺ T-cell stemness and tumor rejection by boosting IL-21-STAT3 signaling.

Autor: Schelker RC; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany. roland.schelker@ukr.de.; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. roland.schelker@ukr.de.; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA. roland.schelker@ukr.de.; Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany. roland.schelker@ukr.de., Fioravanti J; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Mastrogiovanni F; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Baldwin JG; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Rana N; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.; Next Generation Sequencing Core, Leibniz Institute for Immunotherapy, Regensburg, Germany., Li P; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Chen P; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Vadász T; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Spolski R; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Heuser-Loy C; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Slavkovic-Lukic D; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Noronha P; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Damiano G; Immuno-Biotherapy of Melanoma and Solid Tumors Unit, Division of Experimental Oncology, IRCCS Scientific Institute San Raffaele, Milan, Italy.; Vita-Salute San Raffaele University, Milan, Italy., Raccosta L; Immuno-Biotherapy of Melanoma and Solid Tumors Unit, Division of Experimental Oncology, IRCCS Scientific Institute San Raffaele, Milan, Italy., Maggioni D; Immuno-Biotherapy of Melanoma and Solid Tumors Unit, Division of Experimental Oncology, IRCCS Scientific Institute San Raffaele, Milan, Italy., Pullugula S; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Lin JX; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Oh J; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Grandinetti P; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Lecce M; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Hesse L; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.; University of Regensburg, Regensburg, Germany., Kocks E; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.; University of Regensburg, Regensburg, Germany., Martín-Santos A; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Gebhard C; Next Generation Sequencing Core, Leibniz Institute for Immunotherapy, Regensburg, Germany., Telford WG; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Ji Y; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Restifo NP; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Russo V; Immuno-Biotherapy of Melanoma and Solid Tumors Unit, Division of Experimental Oncology, IRCCS Scientific Institute San Raffaele, Milan, Italy.; Vita-Salute San Raffaele University, Milan, Italy., Rehli M; Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.; Next Generation Sequencing Core, Leibniz Institute for Immunotherapy, Regensburg, Germany., Herr W; Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.; National Center for Tumor Diseases, WERA Site, Würzburg-Erlangen-Regensburg-Augsburg, Germany.; Center for Immunomedicine in Transplantation and Oncology, University Hospital Regensburg, Regensburg, Germany., Leonard WJ; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA. leonardw@nhlbi.nih.gov., Gattinoni L; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany. luca.gattinoni@lit.eu.; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. luca.gattinoni@lit.eu.; University of Regensburg, Regensburg, Germany. luca.gattinoni@lit.eu.; Center for Immunomedicine in Transplantation and Oncology, University Hospital Regensburg, Regensburg, Germany. luca.gattinoni@lit.eu.

Publikováno v: Signal transduction and targeted therapy [Signal Transduct Target Ther] 2024 Aug 09; Vol. 9 (1), pp. 199. Date of Electronic Publication: 2024 Aug 09.

Common Features of Environmental Mycobacterium chelonae from Colorado Using Partial and Whole Genomic Sequence Analyses.

Autor: Glauser KG; Department of Science, Principles of Experimental Design in Biotechnology, Rock Canyon High School, Littleton, CO, 80124, USA., Kelley RE; Department of Science, Principles of Experimental Design in Biotechnology, Rock Canyon High School, Littleton, CO, 80124, USA., Leonard WJ; Department of Science, Principles of Experimental Design in Biotechnology, Rock Canyon High School, Littleton, CO, 80124, USA., Hendrix J; Computational Bioscience Program, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA., Petri S; Department of Science, Principles of Experimental Design in Biotechnology, Rock Canyon High School, Littleton, CO, 80124, USA., Tong EI; Aina Informatics Network, 'Iolani School, Honolulu, HI, 96826, USA., Chan YL; Aina Informatics Network, 'Iolani School, Honolulu, HI, 96826, USA., Lipner EM; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA., Dawrs SN; Center for Genes, Environment and Health, National Jewish Health, Denver, CO, 80206, USA., Honda JR; Department of Cellular and Molecular Biology, School of Medicine, University of Texas at Tyler Health Science Center, Tyler, TX, 75708, USA. Jennifer.Honda@UTTyler.edu.

Publikováno v: Current microbiology [Curr Microbiol] 2024 Jan 18; Vol. 81 (2), pp. 69. Date of Electronic Publication: 2024 Jan 18.